Frontiers in Endocrinology · Nov 15, 2026

Case Report: Wernicke encephalopathy precipitated by semaglutide-associated gastrointestinal intolerance in a patient with type 2 diabetes

By Jing Peng, Kun Wang, Lin Qiao

Background: Wernicke encephalopathy (WE) is an acute, potentially fatal neurological emergency caused by thiamine (vitamin B1) deficiency. Although classically linked to alcohol misuse, it increasingly occurs in non-alcoholic patients with malnutrition, malabsorption or protracted vomiting. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide are widely prescribed worldwide, and their characteristic gastrointestinal effects — nausea, vomiting, anorexia and delayed gastric emptying — can produce the nutritional state in which thiamine depletion occurs. Case description: A 40-year-old woman with newly diagnosed type 2 diabetes and no history of alcohol use began subcutaneous semaglutide 0.25 mg once weekly, then developed persistent nausea and vomiting, dizziness and a 2 kg weight loss that persisted after the drug was stopped. Ten days into admission she abruptly developed diplopia, bilateral restriction of abduction, lower-limb weakness and gait instability with slowed mentation. Brain magnetic resonance imaging showed symmetric T2-fluid-attenuated inversion recovery (FLAIR) hyperintensities in the medial thalami, the walls of the third ventricle and the periaqueductal grey matter, with corresponding restricted diffusion on diffusion-weighted imaging (DWI). She received parenteral thiamine (500 mg intravenously daily for 3 days, then 250 mg daily for 4 days) followed by oral thiamine. Her ophthalmoplegia, cognitive slowing and ataxia resolved, and follow-up imaging showed complete regression of the abnormal signal. Discussion and conclusions: GLP-1 RA-associated WE is emerging as a recognisable complication, occurring predominantly in patients with prolonged gastrointestinal intolerance and marked weight loss, and delayed treatment often leaves residual neurological deficits. Clinicians should suspect thiamine deficiency in any patient receiving a GLP-1 RA who develops persistent vomiting, anorexia or rapid weight loss with neurological or ophthalmological symptoms, and should give parenteral thiamine promptly and empirically rather than awaiting biochemical confirmation; prophylactic thiamine supplementation should be considered in high-risk patients.

The paperJournal siteInterventions

AgingResearch.News